Nurix Therapeutics, Inc. has announced the enrollment of the first patient in its Phase 1b/2 clinical trial investigating bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader, in combination ...
Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results